Scholarlink

<p>Cervical cancer is one of the most common gynecological malignancies worldwide. Tumor angiogenesis is a hallmark of cancer, and vascular endothelial growth factor (VEGF) is a potent angiogenic marker. Targeted therapy against VEGF in cervical carcinoma has been found to be effective and prompted us to explore other markers having a role in angiogenesis. B7-H3, an immune checkpoint molecule, is known to promote tumor progression and angiogenesis. However, the relationship between B7-H3 and angiogenesis in cervical carcinoma remains unclear. Hence, we planned to evaluate and compare the immunohistochemical expression of B7-H3 and VEGF in cervical squamous cell carcinoma. This was a retrospective study conducted on 30 histologically diagnosed cervical squamous cell carcinoma cases. Immunohistochemistry for B7-H3 and VEGF was performed in all cases. The <i>H</i>-score for both markers was calculated by multiplying the intensity score with the percentage cell positivity. Data was analyzed using SPSS v 20.0 software. B7-H3 and vascular endothelial growth factor immunopositivity were found in 90% and 96.6% of cervical squamous cell carcinoma cases, respectively. A statistically significant positive correlation was obtained between the <i>H</i>-score of B7-H3 and VEGF (<i>p</i> = 0.000; <i>τ</i> = 0.601). However, the immunoexpression of B7-H3/VEGF had no statistically significant correlation with age, tumor grade, pathological tumor stage, and lymph node metastasis. In view of the immunoregulatory role of B7-H3 and its role in tumor angiogenesis, B7-H3-based targeted therapy might prove to be of utility for treatments and better prognostic outcomes in cervical squamous cell carcinomas.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of B7-H3 and Vascular Endothelial Growth Factor in Cervical Squamous Cell Carcinoma and Its Therapeutic Implications

  • 期刊论文

  • 发表日期：

    2025年7月21日

查看全文
  • Monica Mondal,
  • Preeti Diwaker,
  • Priya Suneja,
  • Karishma Ranjan,
  • Vinod Kumar Arora,
  • Sonal Sharma,
  • Bindiya Gupta

摘要

Cervical cancer is one of the most common gynecological malignancies worldwide. Tumor angiogenesis is a hallmark of cancer, and vascular endothelial growth factor (VEGF) is a potent angiogenic marker. Targeted therapy against VEGF in cervical carcinoma has been found to be effective and prompted us to explore other markers having a role in angiogenesis. B7-H3, an immune checkpoint molecule, is known to promote tumor progression and angiogenesis. However, the relationship between B7-H3 and angiogenesis in cervical carcinoma remains unclear. Hence, we planned to evaluate and compare the immunohistochemical expression of B7-H3 and VEGF in cervical squamous cell carcinoma. This was a retrospective study conducted on 30 histologically diagnosed cervical squamous cell carcinoma cases. Immunohistochemistry for B7-H3 and VEGF was performed in all cases. The H-score for both markers was calculated by multiplying the intensity score with the percentage cell positivity. Data was analyzed using SPSS v 20.0 software. B7-H3 and vascular endothelial growth factor immunopositivity were found in 90% and 96.6% of cervical squamous cell carcinoma cases, respectively. A statistically significant positive correlation was obtained between the H-score of B7-H3 and VEGF (p = 0.000; τ = 0.601). However, the immunoexpression of B7-H3/VEGF had no statistically significant correlation with age, tumor grade, pathological tumor stage, and lymph node metastasis. In view of the immunoregulatory role of B7-H3 and its role in tumor angiogenesis, B7-H3-based targeted therapy might prove to be of utility for treatments and better prognostic outcomes in cervical squamous cell carcinomas.